New Haven-based Achillion Pharmaceuticals Inc. said its stock faces delisting from the Nasdaq because its shareholder equity has fallen below minimum levels to stay on the exchange.
Achillion, developing small-molecule drugs to treat such blood-borne diseases as hepatitis and HIV, said its stockholders’ equity at Sept. 30 was $7.2 million. Nasdaq requires a $10 million minimum equity level.
Achillion said it will submit a definitive plan to return to compliance.
